44 results about "Nephrotoxicity" patented technology

The invention belongs to the technical field of biological medicines, and particularly discloses a novel application of Epiblastatin A in preparation of a medicine for relieving cisplatin-induced acute kidney injury. The application disclosed by the invention for the first time reveals that by inhibiting the activity of Casein Kinase 1 (CK1) kinase, Epiblastine A can obviously relieve renal dysfunction and kidney tissue structure damage caused by cis-platinum. Experiments prove that the compound can effectively reduce serum creatinine and urea nitrogen levels, significantly improve renal tubule pathological injury, down-regulate expression of renal injury early-stage specific biomarkers KIM-1 and NGAL, and definitely inhibit renal tubule epithelial cell apoptosis in an in-vitro model. The invention also provides a specific pharmaceutical composition containing the Epiblastin A and a preparation form of the specific pharmaceutical composition. The invention provides a brand new mechanism and a high-efficiency and low-toxicity treatment strategy for clinically preventing and treating cisplatin dosage-limited renal toxicity, and has important clinical application value.

The invention discloses a human normal kidney immortalized cell line NRC-X1 and application thereof, and belongs to the field of microbial animal cell lines. The human normal kidney immortalized cell line is named as NRC-X1, and the preservation number is CCTCC (China Center For Type Culture Collection) NO: C2025168. The invention also discloses the application of the human normal kidney immortalized cell line NRC-X1 in a virus infection mechanism. The invention also discloses application of the human normal kidney immortalized cell line NRC-X1 in research of drug renal toxicity evaluation. The invention also discloses the application of the human normal kidney immortalized cell line NRC-X1 in bioartificial kidney and cell therapy. The invention also discloses application of the human normal kidney immortalized cell line NRC-X1 in research of kidney physiological and pathological mechanisms.

The invention provides processed rhizoma polygonati polysaccharide, a preparation method thereof and application of the processed rhizoma polygonati polysaccharide in preparation of a medicine for treating renal injury. The nine-processed polygonatum sibiricum polysaccharide is named as NPCP and is composed of fructose and glucose, the NPCP is straight-chain inulin type polysaccharide with the polymerization degree of 12, and the structure of the NPCP is Glcp-(1-) and Fruf-(2-terminal,-1)-Fruf-(2-main chain. According to the obtained uniform nine-process polygonatum polysaccharide NPCP, the protective effect on adenine-induced HK-2 cell injury is achieved by improving the content of renal function markers, improving oxidative stress injury, reducing expression of proinflammatory cytokines, improving intestinal flora disorder and up-regulating short-chain fatty acid in the intestinal tract; more treatment directions are provided for effectively improving adenine-induced renal toxicity by the nine-process polygonatum polysaccharide, and theoretical and experimental bases are provided for clinically finding effective preparation of drugs for treating renal injury.

The invention belongs to the technical field of biological medicine, and particularly relates to application of macrophage LSR gene and / or LSR protein in preparation of drugs and diagnostic products for preventing and / or treating diabetic nephropathy. Research finds that the LSR deletion of macrophages aggravates renal injury by promoting inflammatory response of diabetic nephropathy and increasing lipid renal toxicity; on the contrary, after the LSR expression of the macrophages is recovered, the inflammatory response and lipid droplet deposition of the kidney of the diabetic nephropathy mouse can be effectively reduced, and meanwhile, the kidney injury is improved. Cell experiments show that LSR deletion of macrophages can activate a YAP signal channel to increase secretion of inflammatory factors and reduce low-density lipoprotein uptake at the same time. Therefore, the macrophage LSR can be used as a diabetic nephropathy drug target, a gene therapy target gene and an auxiliary diagnosis marker, and a new theoretical basis and an intervention strategy are provided for prevention and treatment of the disease.

The application provides a method for analyzing the synergistic mechanism of hepatotoxicity and nephrotoxicity of non-steroidal anti-inflammatory drugs. The method comprises the following steps: preliminary toxicity prediction of NSAIDs and collection of toxicity target points, collection of liver and kidney disease target points, then cross and screening of the target points to obtain core target points and common core target points of NSAIDs induced liver and kidney diseases, and then constructing a protein interaction network of the common core target points; enrichment analysis of the common core target points to obtain the common action pathway of NSAIDs induced liver and kidney diseases; finally, further screening of the common core target points to obtain the key target points of NSAIDs induced liver and kidney diseases, and verification by using molecular docking technology. Compared with the traditional method, the advantages of the method are: first, the method does not depend on large-scale patient clinical data and a large number of animal or cell experiments, avoiding the ethical controversy in animal experiments and human experiments; second, the method can identify the potential cross-pathway and synergistic toxicity mechanism when a compound triggers multiple diseases, which is helpful for more comprehensive evaluation of the toxicity risk of NSAIDs.

This invention provides the application of dehydrouncitonin in the preparation of drugs that reduce polymyxin toxicity, belonging to the field of pharmaceutical technology. This invention uses dehydrouncitonin in combination with polymyxin. The combined use of dehydrouncitonin and polymyxin E increased the viability of HEK293T and RAW264.7 cells to 87.7% and 94.3%, respectively, with highly significant differences compared to the control, indicating that treatment with dehydrouncitonin in combination with polymyxin E can significantly inhibit the cytotoxic effect of polymyxin E. This invention uses a mouse model to demonstrate that treatment with dehydrouncitonin in combination with polymyxin E can significantly reduce the neurotoxicity and nephrotoxicity of polymyxin E alone in mice, specifically manifested in improved neurobehavioral effects and improved histopathological effects on brain and kidney tissues. This invention uses dehydrouncitonin in combination with polymyxin E to significantly inhibit the cytotoxic, neurotoxic, and nephrotoxic effects of polymyxin E.

The invention provides application of FXR protein as a target spot in preparation of a medicine for relieving and / or treating renal toxicity of tacrolimus, and belongs to the technical field of biological medicine. The invention proves that the activity or expression level of the FXR protein is regulated in a targeted manner, so that the Tacrolimus-induced renal tubule epithelial cell vacuolation and renal tubule injury can be effectively prevented or relieved, and the abnormal rise of early renal injury markers such as urine NAG enzyme and the like is reduced, thereby directly improving the renal toxicity problem of Tacrolimus. The invention provides a new drug action target and a treatment strategy for clinic, and by developing an FXR agonist or a gene intervention means, the long-term renal injury risk of tacrolimus can be reduced while the anti-rejection curative effect is maintained, the transplanted kidney function and the survival time of a patient are prolonged, and the clinical application prospect is wide. And an effective means is provided for solving the unsatisfied clinical demand of the renal toxicity of the tacrolimus after the transplantation operation.

The disclosure provides means, methods, and compositions of preventing, reducing, and treating kidney failure through the administration of fibroblasts, modified fibroblasts, and / or products derived from fibroblasts. The disclosure may also concern administration of fibroblasts prior to, concurrent with, or subsequent to administration of a nephrotoxic agent results in production of renal function. In some embodiments, fibroblasts are enhanced for augmentation of nephron-regenerative properties through culture under means including hypoxia, histone deacetylase inhibitor treatment, oxytocin, and / or DNA methyltransferase inhibitors.

The invention discloses a folium cortex eucommiae extract and application of the folium cortex eucommiae extract in prevention and treatment of adriamycin nephropathy, and relates to the technical field of medicines, the folium cortex eucommiae extract is prepared from dried folium cortex eucommiae through water extraction, heating at 65 DEG C, ultrasonic assistance and vacuum freeze drying, LC-MS / MS analysis shows that the folium cortex eucommiae extract contains no less than 200 components, the components mainly comprise flavonoids, terpenes and phenylpropanoids, and the content of the flavonoids, the terpenes and the phenylpropanoids is no less than 100%. The folium cortex eucommiae extract has no obvious cytotoxicity to HK-2 and HBZY-1 cells under the concentration of 0-1500mu g / mL, can be used for preparing medicines for preventing and treating adriamycin nephropathy, inhibits kidney cell apoptosis by down-regulating Bax and up-regulating Bcl-2 and obviously reduces the levels of IL-6, IL-1beta and TNF-alpha in serum, and in an animal model, 150-600mg / kg of the folium cortex eucommiae extract is continuously administrated for 21-30 days in an intragastric manner, so that the effect of preventing and treating adriamycin nephropathy is achieved. The traditional Chinese medicine composition can effectively relieve weight loss, reduce urine protein, serum creatinine and urea nitrogen, increase albumin and improve kidney pathological injury, and is suitable for relieving kidney toxicity in a prophylactic or therapeutic mode in subjects receiving adriamycin chemotherapy.

The invention discloses a kidney organoid culture and multifunctional detection integrated micro-fluidic chip, which is characterized in that a first chip (top layer) is provided with six independent cell culture chambers, the bottom is provided with a porous membrane, glomerular cells differentiated by human induced pluripotent stem cells are inoculated, and a blood filtration function is simulated; the second chip (middle layer) is provided with a raw urine-like collecting chamber, and a porous membrane is used for receiving the filtrate and detecting final urine-like components; and the third chip (bottom layer) is inoculated with vascular endothelial cells to simulate renal tubule reabsorption and blood purification processes. According to the invention, glomerular filtration and renal tubule reabsorption full-function chains are coupled, and the limitation of single function simulation is broken through; the parallel culture room supports synchronous drug toxicity testing or disease modeling; a multi-valve dynamic control system can accurately simulate pathological microenvironments such as high glucose and renal toxicity; and in-situ multi-parameter real-time analysis is realized through three paths of detection outlets. The chip provides a highly bionic in-vitro platform for drug screening, diabetic nephropathy mechanism research and kidney injury model construction.

To provide: a nephrotoxicity reducing agent for a pharmaceutical composition containing an antisense oligomer; and a method for reducing nephrotoxicity of the pharmaceutical composition.SOLUTION: In an embodiment, the present invention relates to a nephrotoxicity reducing agent for a pharmaceutical composition including an antisense oligomer. The nephrotoxicity reducing agent includes a sugar alcohol and is used in an amount such that the concentration of the sugar alcohol in the pharmaceutical composition is 1-400 mg / mL.SELECTED DRAWING: Figure 1

The invention provides application of dehydrorhynchophylline in preparation of a medicine for reducing toxicity of polymyxin, and belongs to the technical field of medicines. Dehydrorhynchophylline is combined with polymyxin, the activity of HEK293T and RAW264.7 cells is increased to 87.7% and 94.3% through combined use of the dehydrorhynchophylline and the polymyxin E, the difference is extremely remarkable compared with that of a contrast, and it is indicated that when dehydrorhynchophylline and polymyxin E are combined for treatment, the cytotoxic effect of the polymyxin E can be remarkably inhibited. Mouse model research proves that the combined treatment of dehydrorhynchophylline and polymyxin E can significantly reduce the neurotoxicity and renal toxicity of mice caused by single treatment of polymyxin E, specifically, the improvement effect on neurobehavioristics and the improvement on histopathology of brain tissues and kidney tissues. Dehydrorhynchophylline is combined with polymyxin E, so that the cytotoxicity, neurotoxicity and renal toxicity of the polymyxin E can be remarkably inhibited.

The invention relates to the fields of therapy and drug delivery. It is based on an unexpected finding that a combination of an oligonucleotide-based medicament with a saponin component comprising a penta-cyclic triterpene saponin of a 12,13-dehydrooleanane aglycone core, not only does not appear to be associated with oligonucleotide medicament-induced nephrotoxic effects after systemic administration in vivo, but also that it allows the oligonucleotide-based medicament to enter and act on its nucleic acid target inside of the kidney cells instead of remaining unproductively trapped in renal subcellular compartments or being eliminated into the urine via the renal glomerular filtration system. In line with this finding, herein disclosed are therapeutic combinations, compositions, and formulations, as well as methods of treatment involving their administration, which comprise an oligonucleotide-based medicament that acts on an intracellular nucleic acid target in the kidney cells and / or in the cells of the spleen, being the other blood filtering organ in addition to the kidney, and a saponin component that enables the effective release of said medicament inside of these cells, thus allowing its use at a much lower and safer dose. The provision of the presented herein therapeutic combinations enables effective modulation of gene expression in the kidney and / or spleen cells and, therefore, it opens not only new treatment options for kidney diseases, in particular those involving inflammation and / or splenomegaly, but also for diseases of other organs which affect or are affected by the pathological processes happening in the kidneys and / or in the spleen, in particular being inflammatory processes.

The present application discloses para-aminohippuric acid (PAhI) or a pharmaceutically acceptable salt or carboxylic acid derivative thereof for use in methods for reducing the nephrotoxic side effects of radiolabeled and non-radiolabeled therapeutic and diagnostic compounds in a subject. Also disclosed are pharmaceutical compositions comprising a radiolabeled and / or non-radiolabeled pharmaceutical compound and para-aminohippuric acid (PAH) or a pharmaceutically acceptable salt or carboxylic acid derivative thereof and a pharmaceutically acceptable excipient, diluent, carrier, or combination thereof. Another subject of the present application is a method for reducing the nephrotoxic side effects of radiolabeled and non-radiolabeled therapeutic and diagnostic compounds in a subject, comprising administering to the subject para-aminohippuric acid (PAH) or a pharmaceutically acceptable salt or carboxylic acid derivative thereof in combination with a radiolabeled or non-radiolabeled therapeutic or diagnostic compound.

This invention belongs to the field of medical and pharmaceutical technology, and specifically relates to an antibacterial composition and its application. It comprises osimertinib mesylate and polymyxin. This invention is the first to demonstrate the novel pharmaceutical use of osimertinib mesylate as a synergistic antibacterial adjuvant for polymyxin. Experimental results show that osimertinib mesylate can significantly enhance the antibacterial activity of polymyxin against multidrug-resistant Gram-negative bacteria, effectively reduce the minimum inhibitory concentration of polymyxin, thereby reducing the clinical dosage of polymyxin and lowering the risk of its inherent nephrotoxicity and neurotoxicity. Furthermore, this invention reveals that the combined use of osimertinib mesylate and polymyxin can delay or reverse bacterial resistance to polymyxin, improve the survival rate of infected animal models, and broaden the antibacterial spectrum.

The invention relates to the technical field of pharmaceutical biology, aims to solve the problem of lack of specific detoxification drugs for treating glyphosate poisoning clinically, and particularly provides application of chlorogenic acid in preparation of drugs for treating glyphosate-induced renal toxicity diseases. The drug mechanism of the chlorogenic acid is as follows: glyphosate-induced renal toxicity is antagonized through targeted renal injury biomarkers, wherein the renal injury biomarkers comprise TIM-1, TIMP-2, IGFBP7 and LCN2. The invention also provides a preparation for preventing and / or relieving and / or treating glyphosate-induced renal toxicity diseases, wherein the preparation contains chlorogenic acid. The preparation can be a medicine, a pharmaceutical composition, a health care product, a food or an additive. The medicine prepared by the invention can be used for remarkably reducing the expression levels of TIM-1, TIMP-2, IGFBP7 and LCN2 of the GLY-induced renal injury. In addition, oxidative stress (LCN2), cell cycle arrest (TIMP-2 / IGFBP7) and inflammatory reaction (TIM-1) can be synchronously and accurately inhibited, and the curative effect is superior to that of a current single-channel medicine.

To provide: a nephrotoxicity reducing agent for a pharmaceutical composition containing an antisense oligomer; and a method for reducing nephrotoxicity of the pharmaceutical composition.SOLUTION: In an embodiment, the present invention relates to a nephrotoxicity reducing agent for a pharmaceutical composition including an antisense oligomer. The nephrotoxicity reducing agent includes a sugar other than glucose and is used in an amount such that the concentration of the sugar in the pharmaceutical composition is 1-400 mg / mL.SELECTED DRAWING: Figure 1

The invention discloses application of a metabolic marker in preparation of a product for monitoring CsA renal toxicity and the product, and the metabolic marker can be used for monitoring CsA renal toxicity and is high in sensitivity, rapid, convenient and accurate and reliable in result. The metabolic marker is one or more of the following substances: phospholipid 18: 1 / 20: 0, phospholipid 20: 1 / 14: 1, lysophospholipid 18: 3, sphingolipid d18: 0 / 16: 1OH, sphingolipid d18: 0 / 24: 1OH and monoacylglycerol 20: 4 / 0: 0 / 0: 0.

The application discloses a compound soluble powder of spectinomycin hydrochloride and lincomycin hydrochloride and a preparation method thereof. Compared with the prior art, the compound soluble powder of spectinomycin hydrochloride and lincomycin hydrochloride prepared by the application has high affinity to drugs, is safe to use, significantly improves the drug dissolution speed and stability of the drug after dissolution in water and oil environments, overcomes the problems of insufficient drug dissolution and irritation of the drug to a drug administration site, reduces the hemolytic side effect of the drug for animals and the nephrotoxicity, and can also reduce the drug resistance of the drug for animals by inhibiting the function of P-sugar protein. The compound soluble powder of spectinomycin hydrochloride and lincomycin hydrochloride can expand the antibacterial spectrum and simultaneously prevent and treat various diseases by the synergistic effect of spectinomycin and lincomycin.

This invention belongs to the field of biomaterials technology, specifically relating to an integrated kidney organ-on-a-chip system and its application in online monitoring of pesticide nephrotoxicity. The integrated kidney organ-on-a-chip system includes a sample introduction device, a renal tubular microfluidic chip, a Raman detection platform, and a Raman spectrometer. The labeled antibody probe in the Raman detection platform includes a SERS substrate, and recognition antibodies and signal molecules bound to the SERS substrate. The SERS substrate is a gallium-doped zinc oxide superlattice nanocube material. This invention uses a gallium-doped zinc oxide superlattice nanocube material as the SERS substrate, integrating semiconductor surface-enhanced Raman detection technology into a kidney organ-on-a-chip, providing an online monitoring system for pesticide nephrotoxicity with advantages such as fast analysis speed, high molecular selectivity, and high detection sensitivity.

The invention discloses application of sour cherries or extract thereof in preparation of a medicine for preventing and / or treating renal injury caused by cis-platinum. Experiments find that the sour cherry extract has extremely high free radical scavenging activity, can improve the activity of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) in a body, and has the effect of reducing renal toxicity by inhibiting a molecular mechanism of forming superoxide free radicals through cis-platinum induction; meanwhile, the sour cherry extract has an extremely high nutritional value, can enhance resistance, has medicinal and edible functions, has no toxic or side effect, and can be obtained by ingestion.

The invention relates to a ciprofloxacin dry powder inhalation particle, the dry powder inhalation particle comprises 60-95% by weight of ciprofloxacin hydrochloride and a pharmaceutically acceptable carrier, the mass median aerodynamic diameter (MMAD) of the dry powder inhalation particle is 1-5 [mu] m, and the geometric particle size distribution is that D10 is less than or equal to 2.0 [mu] m, D50 is less than or equal to 4.5 [mu] m, and D90 is less than or equal to 8.0 [mu] m. The dry powder inhalation particle can target high-concentration deposition of a lung infection part, the bioavailability is remarkably improved, and risks of renal toxicity, ototoxicity, drug resistance and the like are reduced.

The application belongs to the technical field of traditional Chinese medicines, and relates to a uremia clearing tablet and a preparation method thereof. The uremia clearing tablet comprises the following raw materials in parts by mass: 40 parts of rhubarb, 36 parts of licorice, 160 parts of astragalus, 120 parts of mulberry bark, 80 parts of sophora, 120 parts of codonopsis, 200 parts of atractylodes, 200 parts of poria, 120 parts of white peony root, 1000 parts of chrysanthemum, 200 parts of prepared rehmannia, 120 parts of chuanxiong, 200 parts of salvia, 80 parts of pinellia, 200 parts of plantain, 60 parts of bupleurum, 400-600 parts of pregelatinized starch, 100-200 parts of hydroxypropyl-beta-cyclodextrin, 80-150 parts of co-processed material, 70-100 parts of low-substituted hydroxypropyl cellulose, 10-15 parts of anhydrous calcium hydrogen phosphate, 5-8 parts of fumaric acid and 22-32 parts of lubricant. The uremia clearing tablet provided by the application has good formability, short disintegration time and good stability without coating.

The invention relates to the technical field of drug carriers, in particular to a preparation method and application of self-assembled glycyrrhizic acid supported paeoniflorin nano-micelles. The preparation method adopts a membrane separation method and comprises the steps of solution preparation, membrane formation, hydration, particle size homogenization and purification. The prepared glycyrrhizic acid loaded paeoniflorin nano-micelle can be used for preparing medicines for treating liver cancer. According to the invention, the nano-micelle with the particle size in the range of 100-150nm can be stably prepared. The micelles can be efficiently taken by liver cells and are enriched in parenchymal liver cells in a targeted manner. Meanwhile, the targeted enrichment of the liver can reduce the kidney distribution of the medicine, so that the occurrence rate of pseudoaldosterone is reduced, and the renal toxicity of the medicine is reduced. According to the present invention, the cytotoxicity of the drug on normal liver cells is not increased while the inhibition effect on the liver cancer cell HepG2 can be significantly increased so as to provide the new strategy and the new treatment scheme for reducing the treatment dose, reducing the side effect or overcoming the drug resistance in the clinical application.

The application belongs to the technical field of drug screening, analytical chemistry and pharmacology, and specifically discloses a method for screening traditional Chinese medicine active ingredients based on anti-chemotherapy drug nephrotoxicity and evaluating drug interactions. By constructing an OCT2 high-expression stable cell strain, using styrene-maleic anhydride copolymer to form OCT2 nanoliposomes, and covalently fixing the nanoliposomes on ethylene sulfone-based silica gel, an OCT2 cell membrane chromatographic column with high stability and high activity is prepared. Based on the OCT2 cell membrane chromatographic column, a two-dimensional biochromatographic method for specifically screening OCT2 binding components from traditional Chinese medicine extracts is established. With OCT2 as a specific target, the application combines high-bionic cell membrane chromatography technology, two-dimensional chromatography-mass spectrometry technology, in-vitro binding kinetics analysis, competitive drug interaction evaluation, computer simulation and in-vivo pharmacodynamic verification, and forms a complete research system from discovery to drug interaction evaluation and then to in-vivo confirmation.

This invention provides an application of *Lactobacillus plantarum* peptidoglycan in the preparation of uric acid-lowering products, relating to the biomedical field. This *Lactobacillus plantarum* peptidoglycan is derived from *Lactobacillus plantarum* (accession number CGMCC No. 25306). Lactobacillus plantarum Extracted from YC, its chemical structure is A1γ. This plant lactobacillus peptidoglycan can regulate uric acid homeostasis through multiple synergistic mechanisms: inhibiting hepatic XOD activity to reduce uric acid production; bidirectionally regulating renal and intestinal uric acid transport proteins (upregulating ABCG2 / OAT1, downregulating URAT1 / GLUT9) to promote excretion; and exerting systemic anti-inflammatory and hepatoprotective effects. This plant lactobacillus peptidoglycan has a significant uric acid-lowering effect without hepatotoxicity or nephrotoxicity, and its safety is superior to allopurinol. This invention provides a novel core material basis and solution for developing multi-pathway, highly safe uric acid-lowering products.

The invention relates to the fields of therapy and drug delivery. It is based on an unexpected finding that a combination of an oligonucleotide-based medicament with a saponin component comprising a penta-cyclic triterpene saponin of a 12,13-dehydrooleanane aglycone core, not only does not appear to be associated with oligonucleotide medicament-induced nephrotoxic effects after systemic administration in vivo, but also that it allows the oligonucleotide-based medicament to enter and act on its nucleic acid target inside of the kidney cells instead of remaining unproductively trapped in renal subcellular compartments or being eliminated into the urine via the renal glomerular filtration system. In line with this finding, herein disclosed are therapeutic combinations, compositions, and formulations, as well as methods of treatment involving their administration, which comprise an oligonucleotide-based medicament that acts on an intracellular nucleic acid target in the kidney cells, and a saponin component that enables the effective release of said medicament inside of the kidney cells, thus allowing its use at a much lower and safer dose. The provision of the presented herein therapeutic combinations enables effective modulation of gene expression in the kidney cells and, therefore, it opens not only new treatment options for kidney diseases, but also for diseases of other organs which affect the kidneys and / or which are affected by inefficient or impaired kidney function.

The invention relates to a B cell inhibitor and application thereof in preparation of drugs for treating xerophthalmia. The present invention relates to a B cell activity inhibitor selected from the group consisting of formononetin; formononin; astragaloside IV; total flavonoids of an astragalus extract; the components are astragaloside IV and formononetin; astragaloside IV and formononin; the composition is prepared from astragaloside I, astragaloside IV, formononin and formononetin. Compared with the side effect of cyclosporine in the prior art (which is within the renal toxicity of 1 / 3 of a patient who takes the medicine), the astragalus extract general flavone has the effect of inhibiting the activity of B cells so as to inhibit humoral immunity. On the basis of the research on the disease mechanism of pSS, the specific astragalus membranaceus extract general flavone which can be used as a medicine for administration and a medicine for instillation is developed.

The disclosure provides means, methods, and compositions of preventing, reducing, and treating kidney failure through the administration of fibroblasts, modified fibroblasts, and / or products derived from fibroblasts. The disclosure may also concern administration of fibroblasts prior to, concurrent with, or subsequent to administration of a nephrotoxic agent results in production of renal function. In some embodiments, fibroblasts are enhanced for augmentation of nephron-regenerative properties through culture under means including hypoxia, histone deacetylase inhibitor treatment, oxytocin, and / or DNA methyltransferase inhibitors.

The application belongs to the field of microorganism animal cell lines, and relates to a human normal kidney immortalized cell line NRC-X1 and application thereof. The human normal kidney immortalized cell line is named NRC-X1, and the preservation number is CCTCC NO: C2025168. The application of the human normal kidney immortalized cell line NRC-X1 in a virus infection mechanism. The application of the human normal kidney immortalized cell line NRC-X1 in research on drug nephrotoxicity evaluation. The application of the human normal kidney immortalized cell line NRC-X1 in a biological artificial kidney and cell therapy. The application of the human normal kidney immortalized cell line NRC-X1 in research on kidney physiological and pathological mechanisms.